- Merck signs MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies
- Integrates Merck’s BioContinuum™ Platform in Mycenax’s Contract Development and Manufacturing Services (CDMO) for maximum safety, control, transparency, and repeatability
- Collaboration aims to enhance process intensification, advance towards BioProcessing 4.0 and continuous bioprocessing
Taipei, Taiwan, January 24, 2024 – Merck, a leading science and technology company, has signed a Memorandum of Understanding (MoU) with Mycenax Biotech to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets. The agreement includes the integration of Merck’s BioContinuum™ Platform in the entire bioprocessing spectrum for Mycenax’s customers, followed by automation and digitalization of processes.
"Digital transformation in biomanufacturing is creating a paradigm shift towards a bioprocessing facility-of-the-future that is data-intensified, connected and seamless in continuous processing,” said Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck. “By combining the strengths of Merck and Mycenax in Contract Development and Manufacturing Services, we aim to accelerate the development of new products and process innovations. This will enhance resilience in both research and production.”
As part of the agreement, Merck will offer Mycenax extensive support including consultation, technical assistance, and training, ensuring stakeholders receive expert guidance for optimal performance. Recognizing the importance of economic viability, the collaboration will also incorporate in-depth cost modelling for better process economics. This strategic analysis aims to enhance cost-effectiveness in next generation bioprocessing.
"Mycenax consistently seeks better solutions and areas for optimization. The integration of continuous processing and Industry 4.0 is not only a future mainstream trend but also possesses the potential for continuous growth," said Pei-Jiun Chen, Ph.D., Chairman/CEO and President of Mycenax. "The collaboration with Merck aims to provide innovative continuous processing solutions in the market, to boost our international standing and cater to diverse biopharmaceutical needs."
Photo caption: Gladys Wang (L), Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck, with Dr. Pei-Jiun Chen (R), Chairman/CEO and President of Mycenax, inked the partnership on January 24, 2024.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.05 billion NTD (~66.3 million USD).
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com.tw
- Merck signs MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies
- Integrates Merck’s BioContinuum™ Platform in Mycenax’s Contract Development and Manufacturing Services (CDMO) for maximum safety, control, transparency, and repeatability
- Collaboration aims to enhance process intensification, advance towards BioProcessing 4.0 and continuous bioprocessing
Taipei, Taiwan, January 24, 2024 – Merck, a leading science and technology company, has signed a Memorandum of Understanding (MoU) with Mycenax Biotech to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets. The agreement includes the integration of Merck’s BioContinuum™ Platform in the entire bioprocessing spectrum for Mycenax’s customers, followed by automation and digitalization of processes.
"Digital transformation in biomanufacturing is creating a paradigm shift towards a bioprocessing facility-of-the-future that is data-intensified, connected and seamless in continuous processing,” said Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck. “By combining the strengths of Merck and Mycenax in Contract Development and Manufacturing Services, we aim to accelerate the development of new products and process innovations. This will enhance resilience in both research and production.”
As part of the agreement, Merck will offer Mycenax extensive support including consultation, technical assistance, and training, ensuring stakeholders receive expert guidance for optimal performance. Recognizing the importance of economic viability, the collaboration will also incorporate in-depth cost modelling for better process economics. This strategic analysis aims to enhance cost-effectiveness in next generation bioprocessing.
"Mycenax consistently seeks better solutions and areas for optimization. The integration of continuous processing and Industry 4.0 is not only a future mainstream trend but also possesses the potential for continuous growth," said Pei-Jiun Chen, Ph.D., Chairman/CEO and President of Mycenax. "The collaboration with Merck aims to provide innovative continuous processing solutions in the market, to boost our international standing and cater to diverse biopharmaceutical needs."
Photo caption: Gladys Wang (L), Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck, with Dr. Pei-Jiun Chen (R), Chairman/CEO and President of Mycenax, inked the partnership on January 24, 2024.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
About Mycenax
Mycenax takes the CDMO brand positioning of "big D and medium M" with "Innovative development abilities (D) and Adequate manufacturing capacity (M)" to provides one-stop services for the development and manufacture of traditional biologics and novel biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 2.05 billion NTD (~66.3 million USD).
Stock code: Mycenax Biotech (4726).
Company website: http://www.mycenax.com.tw